Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.
CO Lawmakers Tweak Last Year’s First-In-Nation AI Law In a special session that began last week, Colorado Senate Majority Leader Robert Rodriguez (D) introduced legislation ( SB 4 a ) that would...
States Seek Ways to Replace Expiring Federal Health Subsidies Policymakers in California, Colorado, Maryland and other states are considering ways to backfill pandemic-era federal health insurance subsidies...
The price of electricity has risen faster than inflation since 2022, and the U.S. Energy Information Administration (EIA) expects that trend to continue through 2026 . In the past year, the cost of electricity...
Trump’s ‘Debanking’ Order Raises Questions for Lenders Days after accusing JPMorgan Chase and Bank of America of discriminating against him and other conservatives, President Donald...
Tech Groups Battling AI Regulation in CA Tech industry groups including the Business Software Alliance, the Consumer Technology Association and the Chamber of Progress are stepping up their lobbying...
* The views expressed in externally authored materials linked or published on this site do not necessarily reflect the views of LexisNexis Legal & Professional.
California joined a nationwide movement to tighten restrictions on pharmacy benefit managers with the approval of SB 966 days before adjourning its legislative session on Aug. 31. If signed by Gov. Gavin Newsom (D) the measure will establish licensing requirements for PBMs and require them to report to the state’s Department of Insurance the fees they charge pharmacies and the rebates they receive from drug manufacturers. The bill would also require PBMs to pass along 100% of those rebates to health plans or insurers. (PLURIBUS NEWS, LEXISNEXIS STATE NET)
In 2021, Arkansas became the first state to pass a law requiring pharmaceutical manufacturers that participate in Medicaid to sell drugs to contract pharmacies at a discount under the federal 340B program. Louisiana followed suit in 2023. This year, Kansas (SB 28), Maryland (HB 1056), Mississippi (HB 728), Missouri (SB 751) and West Virginia (SB 325) enacted similar legislation. And other states, including New York (AB 7789), considered similar measures.
The recent legislative actions are pushback against the restriction of 340B drug sales by pharmaceutical companies, which contend the 340B program has expanded beyond its original intent. As of September 2023, 25 drugmakers had done so. (STATELINE)
—Compiled by SNCJ Managing Editor KOREY CLARK
Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.